secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2021-12-03T23:59:59+00:00
Accession:  0001178913-21-003771
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab CMO Aharon resigns; Weiner appointed Interim CMO
---------------------------------------------------------

- Dr. Arnon Aharon resigned as CMO effective Feb 1, 2022; will continue 60 days and as senior advisor.
- Dr. David M. Weiner appointed Interim CMO effective immediately, part-time, based in U.S.
- Dr. Weiner has 25+ years experience; previously CEO of Amathus Therapeutics, CMO at Lumos Pharma and aTyr Pharma.
- Resignation not due to any disagreement with company or board.
- Chemomab advancing CM-101 clinical programs in fibrotic/inflammatory diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003771/0001178913-21-003771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003771/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-21-003771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer